| Name | Title | Contact Details |
|---|---|---|
Sherry Schnell |
Chief Compliance Officer and Associate General Counsel | Profile |
Malcolm Lloyd-Smith |
Chief Regulatory Officer | Profile |
Ingrid Delaet |
Chief Regulatory Officer | Profile |
David Bradfute |
Vice President and Head, Intellectual Property | Profile |
Darin Lippoldt |
Chief Legal Officer | Profile |
DMC is leading the low cost sustainable transformation of multiple product markets.
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Inhibitex, Inc. is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Incellico Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.